Company
BiVictriX Therapeutics Limited
LON:BVX
BiVictriX Therapeutics PLC is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities. The company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni ® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni ® fingerprints", on tumour cells, which are largely absent from healthy cells.
42 stories · page 2 of 3
BiVictriX sees positive final data in BVX001 leukaemia drug study
US patent claims progressing for lead clinical cancer treatment candidate
BiVictriX Therapeutics reveals healthy cash levels in H1
The biotech company invested £1.2mln into research and development in the six months ended 30 June
BiVictriX will be ready to nominate lead candidate in Q4
The biotech provided a wide-ranging progress report
AstraZeneca has cracked a whole new cancer treatment market, but how much is worth?
A bunch of smaller companies are following in AZ's wake developing the next generation of antibody drug conjugates
BiVictriX to speed up process of identifying promising cancer therapies
The platform would increase the speed from discovery to lead generation and reduce development time for the pipeline.
BiVictriX Therapeutics adds two new potential cancer therapies to its portfolio
Chief executive Tiffany Thorn said the decision to move forward with the new early-stage assets was a “significant milestone”
BiVictriX Therapeutics looks to bolster its intellectual property base with four patent applications
The biotech is developing very targeted cancer treatments that aim to reduce the collateral damage done by the drug
BiVictriX Therapeutics appoint new CFO
The newcomer will take a position in a non-board role
Archive
Small Cap Wrap - Bivictrix, Cohort, Croma Security Solutions and more...
BiVictriX Therapeutics, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience announced a collaboration to manufacture BiVictriX’s a
BiVictriX Therapeutics, Abzena team up to create next generation of cancer antibody-drug conjugates
The company is developing an anti-cancer technology that works with superior specificity while eradicating collateral damage
BiVictriX reports progress on new cancer treatment
BVX001 is in preclinical development for Acute Myeloid leukaemia, one of the most aggressive forms of blood cancer